(19)
(11) EP 3 258 847 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
10.07.2024 Bulletin 2024/28

(45) Mention of the grant of the patent:
29.05.2024 Bulletin 2024/22

(21) Application number: 16708023.3

(22) Date of filing: 11.02.2016
(51) International Patent Classification (IPC): 
A61B 5/145(2006.01)
A61B 5/1459(2006.01)
 A61B 5/07(2006.01)
A61B 5/1473(2006.01)
(52) Cooperative Patent Classification (CPC):
A61B 2560/063; A61B 5/6846; A61B 5/0002; A61B 5/07; A61B 5/14503; A61B 5/14546; A61B 5/14735; A61B 2560/0412; A61B 5/6833; A61B 5/1451; A61B 5/1459; A61B 5/6848; A61B 5/14532
(86) International application number:
PCT/US2016/017512
(87) International publication number:
WO 2016/133778 (25.08.2016 Gazette 2016/34)

(54)

CONTINUOUS GLUCOSE MONITORING SYSTEM

KONTINUIERLICHES BLUTZUCKERÜBERWACHUNGSSYSTEM

SYSTÈME DE SURVEILLANCE DE LA GLYCÉMIE EN CONTINU

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 16.02.2015 US 201514623012

(43) Date of publication of application:
27.12.2017 Bulletin 2017/52

(73) Proprietor: Verily Life Sciences LLC
South San Francisco, CA 94080 (US)

(72) Inventors:
  • LIU, Zenghe
    Mountain View, CA 94043 (US)
  • OTIS, Brian
    Mountain View, CA 94043 (US)
  • WASSON, Jaclyn Leverett
    Mountain View, CA 94043 (US)
  • BIEDERMAN, William James
    Mountain View, CA 94043 (US)

(74) Representative: Mewburn Ellis LLP 
Aurora Building Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB)


(56) References cited: : 
WO-A1-2014/159229
US-A1- 2007 073 129
US-A1- 2010 198 034
 WO-A2-2014/145484
US-A1- 2008 009 692
US-A1- 2012 018 302
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).